UNSPSC 51162741: Taurosteine

This classification denotes a mucolytic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 43A07PH183. European Medicines Agency schedules Taurosteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10840MIG. Taurosteine generally arises in the molecular formula C7H9NO4S2.

UNSPSC 51162741 Taurosteine is a Commodity code that captures pharmaceutical and health-supply procurement by state and local government bodies, though recent solicitations show activity focused on naloxone, drug deactivation systems, and broader generic pharmaceuticals rather than taurosteine specifically. State and local purchasers under this code include county health departments and cooperative purchasing alliances serving multiple state and local jurisdictions. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, are active buyers in this space. The work being solicited ranges from point-of-use health-supply procurement—such as naloxone and drug deactivation systems for community health initiatives—to large-scale, multi-state generic pharmaceutical and OTC product supply contracts serving numerous state and local government facilities across participating jurisdictions.

Recent procurement activity centers in Florida and Minnesota. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida and a response deadline of July 26, 2023. MMCAP issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, including Oregon, with responses due March 26, 2026 and contract effectiveness set for July 1, 2026. Both solicitations require vendor compliance with federal regulatory standards, comprehensive insurance coverage, and product traceability; MMCAP additionally mandates cGMP certification, Drug Supply Chain Security Act compliance, and relationships with authorized wholesalers. The code shows limited recent activity and the actual taurosteine-specific solicitation volume cannot be determined from available records.